U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07483242) titled 'Individualized Surgical Guidance in HCC-BDTT' on March 08.
Brief Summary: The Rboost causal model can identify patients who are most likely to benefit among HCC-BDTT patients. Adherence to the individualized recommendation improves survival. This data-driven tool offers vital support for precision surgical decision-making in this high-risk disease.
Study Start Date: Aug. 01, 2024
Study Type: OBSERVATIONAL
Condition:
Hepatocellular Carcinoma (HCC)
Intervention:
PROCEDURE: Bile Duct Resection
This group includes biliary/enteric reconstruction, bile duct resection with thrombectomy, and biliary tract interventions
Recruitment ...